

# CYRAMZA®

ramucirumab [rmc] concentrate for intravenous infusion

## NAME OF THE MEDICINE


### Non-proprietary Name

Ramucirumab [rmc]

### Chemical Structure

Ramucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.

Ramucirumab is a human monoclonal antibody composed of 2 heavy chain ( $\gamma$ 1-chain) molecules consisting of 446 amino acid residues each and 2 light chain ( $\kappa$ -chain) molecules consisting of 214 amino acid residues each.



The average molecular mass of ramucirumab with the predominant form of N-linked glycosylation is 146,756 Da.

The CAS number is 947687-13-0.

## DESCRIPTION

CYRAMZA is available as a concentrate in 10 mL or 50 mL single-use vials. CYRAMZA is a sterile, clear to slightly opalescent and colourless to slightly yellow solution without visible particles. Each vial contains either 100 mg ramucirumab in 10 mL (10 mg/mL) or 500 mg ramucirumab in 50 mL (10 mg/mL). After dilution and preparation, CYRAMZA is administered as an intravenous infusion. CYRAMZA contains the excipients histidine, histidine hydrochloride monohydrate, glycine, sodium chloride, polysorbate 80 and water for injections.

## **PHARMACOLOGY**

### **Pharmacodynamics**

#### Mechanism of Action

VEGF Receptor 2 is the key mediator of VEGF induced angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells.

#### Immunogenicity

Overall, there was a low incidence of both treatment emergent anti-drug antibodies and neutralising antibodies among ramucirumab-treated patients, and no correlation with safety outcomes in these patients. There was no relationship between immunogenicity and infusion-related reactions (IRRs) or treatment emergent adverse events. There is insufficient data to evaluate the effects of anti-drug antibodies (ADAs) on the efficacy or safety of ramucirumab.

### **Pharmacokinetics**

#### Absorption

Ramucirumab is administered as an intravenous infusion. There have been no studies performed with other routes of administration.

#### Distribution

Following the dose regimen of 8 mg/kg ramucirumab (single agent) every 2 weeks, the geometric means of ramucirumab  $C_{min}$  were 49.5 µg/mL (range of 6.3-228 µg/mL) and 74.4 µg/mL (range of 13.8-234 µg/mL) prior to administration of the fourth and seventh dose, respectively, in serum from patients with advanced gastric adenocarcinoma. Based on population pharmacokinetic approach (PopPK), the mean volume of distribution at steady state for ramucirumab was 5.5 L for gastric adenocarcinoma patients.

#### Metabolism

The metabolism of ramucirumab has not been studied. Antibodies are principally cleared by catabolism.

#### Elimination

Based on PopPK, the mean clearance of ramucirumab was 0.014 L/hr and the mean half-life was 15 days for gastric adenocarcinoma patients.

#### Special Populations

PopPK analysis suggested age, gender, body weight, and race had no effect on the PK of ramucirumab.

### Elderly Patients

Based on the results of the PopPK analysis, there was no difference in ramucirumab exposure in patients  $\geq 65$  years of age compared to patients  $< 65$  years old.

### Renally Impaired Patients

No formal studies have been conducted to evaluate the effect of renal impairment on the PK of ramucirumab. Based on the results of the PopPK analysis, ramucirumab exposure was similar in patients with mild renal impairment (calculated creatinine clearance [CrCl]  $\geq 60$  to  $< 90$  mL/min) and moderate renal impairment (CrCL  $\geq 30$  to  $< 60$  mL/min) as to patients with normal renal function (CrCl  $\geq 90$  mL/min). No data were available from patients with severe renal impairment (CrCl  $< 30$  mL/min).

### Hepatically Impaired patients

No formal studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of ramucirumab.

### Exposure response relationships: RAINBOW

Exposure-response analyses indicated that efficacy and specific measures of safety of ramucirumab were correlated with ramucirumab exposure. Increased efficacy, as measured by improvements in OS and PFS, was associated with increasing ramucirumab exposure range which was produced by 8 mg/kg ramucirumab given on days 1 and 15 of a 28 day cycle. The incidences of Grade  $\geq 3$  hypertension, neutropenia, and leukopenia were also increased with higher ramucirumab exposure (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

### Exposure response relationship: REGARD

Based on limited PK data, exposure-response analysis suggested that efficacy of ramucirumab was correlated with ramucirumab exposure.

## **CLINICAL TRIALS**

### RAINBOW

RAINBOW, a multinational, randomised, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel, was conducted in 665 patients with locally advanced or metastatic gastric adenocarcinoma (including adenocarcinoma of the gastro-oesophageal junction [GEJ]) following platinum- or fluoropyrimidine-containing chemotherapy with or without anthracycline. The primary endpoint was overall survival (OS) and secondary endpoints included progression-free survival (PFS) and overall response rate (ORR). Patients were required to have experienced disease progression during, or within 4 months after the last dose of first-line therapy with ECOG performance status (PS) 0-1.

Patients were randomised in a 1:1 ratio to receive ramucirumab plus paclitaxel (n=330) or placebo plus paclitaxel (n=335). Randomisation was stratified by geographic region,

time to progression from the start of first-line therapy (<6 months versus ≥6 months) and disease measurability. Ramucirumab at 8 mg/kg or placebo was administered by intravenous infusion every 2 weeks (on days 1 and 15) of a 28-day cycle. Paclitaxel at 80 mg/m<sup>2</sup> was administered by intravenous infusion on days 1, 8 and 15 of each 28-day cycle.

A majority (75%) of patients randomised in the study received prior platinum/fluoropyrimidine combination therapy without an anthracycline. The remainder (25%) received prior platinum/fluoropyrimidine combination therapy with an anthracycline. Two-thirds of the patients experienced disease progression while still on first-line therapy (66.8%). Baseline patient demographics and disease characteristics were generally balanced between the study arms. The median age was 61 years; 71% of the patients were male; 61% were Caucasian, 35% Asian; the ECOG PS was 0 for 39% of patients, 1 for 61% of patients; 81% of patients had measurable disease and 79% had gastric adenocarcinoma; 21% had GEJ adenocarcinoma. The majority of patients (76%) had experienced disease progression within 6 months from the start of first-line therapy.

For patients treated with ramucirumab plus paclitaxel the median duration of therapy was 19 weeks, and for patients treated with placebo plus paclitaxel the median duration of therapy was 12 weeks. The median relative dose intensity of ramucirumab was 98.6% and of placebo was 99.6%. The median relative dose intensity of paclitaxel was 87.7% for the ramucirumab plus paclitaxel arm and 93.2% for the placebo plus paclitaxel arm. A similar percentage of patients discontinued treatment due to adverse events: 12% of patients treated with ramucirumab plus paclitaxel compared with 11% of patients treated with placebo plus paclitaxel. Post discontinuation systemic anti-cancer therapy was given to 47.9% of patients receiving ramucirumab plus paclitaxel and 46.0% of patients receiving placebo plus paclitaxel.


Refer to table 1 shown below for efficacy outcomes on Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR).

**Table 1: Summary of Efficacy Data – Intent to Treat (ITT) Population**

	<b>Ramucirumab + Paclitaxel N = 330</b>	<b>Placebo + Paclitaxel N = 335</b>
Overall Survival, months		
Median (95% CI)	9.6 (8.5, 10.8)	7.4 (6.3, 8.4)
Hazard Ratio (95% CI)	0.807 (0.678, 0.962)	
Stratified Log-rank p-value	0.0169	
Progression-Free Survival, months		
Median (95% CI)	4.4 (4.2, 5.3)	2.9 (2.8, 3.0)
Hazard Ratio (95% CI)	0.635 (0.536, 0.752)	
Stratified Log-rank p-value	<0.0001	
Objective Response		
Objective Response Rate (CR+PR) 95% CI	27.9% (23.3%, 33.0%)	16.1% (12.6%, 20.4%)
Odds Ratio (95% CI)	2.14 (1.45, 3.16)	
Stratified CMH p-value	0.0001	


Abbreviations: CI = confidence interval, CR = complete response, PR = partial response, CMH = Cochran-Mantel-Haenszel  
*Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≥2 patients*  
 Patients with ECOG score ≥2 were excluded from the pivotal studies, therefore the safety and efficacy of Cyramza in this patient population is unknown.

**Figure 1: Kaplan-Meier Curves of Overall Survival for Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in RAINBOW**



Abbreviations: Pac = paclitaxel; Plc = placebo; Ram = ramucirumab

**Figure 2: Kaplan-Meier Curves of Progression-free Survival for Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in RAINBOW**



Number at Risk																								
	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
Ram+Pac	330	259	188	104	70	43	28	15	11	7	3	1												
Plc+Pac	335	214	124	50	34	21	12	8	5	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3

Abbreviations: Pac = paclitaxel; Plc = placebo; Ram = ramucirumab

## REGARD

REGARD, a multinational, randomised, double-blind, multicentre study of ramucirumab plus best supportive care (BSC) versus placebo plus BSC, was conducted in 355 patients with locally advanced or metastatic gastric adenocarcinoma (including adenocarcinoma of the gastro-oesophageal junction [GEJ]) following platinum- or fluoropyrimidine-containing chemotherapy. The primary endpoint was overall survival (OS) and secondary endpoints included progression-free survival (PFS) and 12 week PFS rate. Patients were required to have experienced disease progression during first-line treatment or within 4 months after the last dose of first-line therapy for metastatic disease, or during adjuvant treatment or within 6 months after the last dose of adjuvant therapy, and had Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. Patients were randomised in a 2:1 ratio to receive an intravenous infusion of ramucirumab 8 mg/kg (n=238) or placebo (n=117) every 2 weeks. Randomisation was stratified by weight loss over the prior 3 months ( $\geq 10\%$  versus  $< 10\%$ ), geographic region, and location of the primary tumour (gastric versus GEJ).

Patients enrolled in the study received prior platinum/fluoropyrimidine combination therapy (81%), fluoropyrimidine-containing regimens without platinum (15%), or platinum-containing regimens without fluoropyrimidine (4%). With respect to baseline demographics and disease characteristics: the median age was 60 years; 70% of patients were male; 77% were Caucasian, 16% Asian; the ECOG PS was 0 for 28% of patients and 1 for 72% of patients; 91% of patients had measurable disease; and 75%

of patients had gastric adenocarcinoma, 25% adenocarcinoma of the GEJ. The majority of patients (85%) had experienced disease progression during first-line treatment or following first-line therapy and the remainder during or following adjuvant therapy. Patients received a median of 4 cycles (range 1-34) of ramucirumab and 3 cycles (range 1-30) of placebo.

The median relative dose intensity of ramucirumab was 99.6%. Eleven percent of patients treated with ramucirumab and 6% of patients on placebo discontinued therapy due to adverse events. Overall survival was statistically significantly improved in patients receiving ramucirumab as compared with patients receiving placebo (hazard ratio [HR] 0.776; 95% CI: 0.603 to 0.998; p=0.0473), corresponding to a 22% reduction in the risk of death and an increase in median survival to 5.2 months for ramucirumab from 3.8 months for placebo. Progression-free survival was statically significantly improved in patients receiving ramucirumab as compared with patients receiving placebo (HR 0.483; 95% CI: 0.376 to 0.620; p<0.0001), corresponding to a 52% reduction in the risk of progression or death and an increase in median PFS to 2.1 months for ramucirumab from 1.3 months for placebo. Efficacy results are shown in Table 2.

**Table 2: Summary of Efficacy Data – Intent to Treat (ITT) Population**


	<b>Ramucirumab N=238</b>	<b>Placebo N=117</b>
<b>Overall Survival, months</b>		
Median (95% CI)	5.2 (4.4, 5.7)	3.8 (2.8, 4.7)
Hazard Ratio (95% CI)	0.776 (0.603, 0.998)	
Stratified Log-rank p-value	0.0473	
<b>Progression-Free Survival, months</b>		
Median (95% CI)	2.1 (1.5, 2.7)	1.3 (1.3, 1.4)
Hazard Ratio (95% CI)	0.483 (0.376, 0.620)	
Stratified Log-rank p-value	<0.0001	
12-week PFS rate % (95% CI)	40.1 (33.6, 46.4)	15.8 (9.7, 23.3)

Abbreviations: CI = confidence interval


*Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≥2 patients*

Patients with ECOG score ≥2 were excluded from the pivotal studies, therefore the safety and efficacy of Cyramza in this patient population is unknown.

**Figure 3: Kaplan-Meier Curves of Overall Survival for Ramucirumab versus Placebo in REGARD**



**Figure 4: Kaplan-Meier Curves of Progression-free Survival for Ramucirumab versus Placebo in REGARD**



## **INDICATIONS**

CYRAMZA, in combination with paclitaxel, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.

CYRAMZA, as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy when treatment in combination with paclitaxel is not appropriate.

## **CONTRAINDICATIONS**

CYRAMZA is contraindicated in patients with known hypersensitivity to ramucirumab or to any of the excipients in the product.

## **PRECAUTIONS**

### **Neutropenia**

Severe neutropenia has been reported in clinical trials with ramucirumab in combination with chemotherapy. Blood counts should be monitored in patients receiving ramucirumab in combination with chemotherapy.

### **Arterial Thromboembolic Events**

Serious, sometimes fatal, arterial thromboembolic events (ATEs) including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia have been reported in clinical trials. Permanently discontinue ramucirumab in patients who experience a severe ATE (see DOSAGE and ADMINISTRATION).

### **Gastrointestinal Perforations**

Cases, sometimes fatal, of gastrointestinal perforation have been reported in patients treated with ramucirumab. Permanently discontinue ramucirumab in patients who experience gastrointestinal perforations (see DOSAGE and ADMINISTRATION).

### **Severe Bleeding**

Severe gastrointestinal haemorrhage including fatal events were reported in patients with gastric adenocarcinoma treated with ramucirumab in combination with paclitaxel.

Ramucirumab is an antiangiogenic therapy and has the potential to increase the risk of severe bleeding. Ramucirumab should be permanently discontinued in patients who experience Grade 3 or 4 bleeding (see DOSAGE and ADMINISTRATION). Blood counts and coagulation parameters should be monitored in patients with conditions predisposing to bleeding, and in those treated with anticoagulants or other concomitant medicinal products that increase the risk of bleeding.

### **Infusion-Related Reactions**

Infusion-related reactions (IRR) were reported in clinical trials with ramucirumab. The majority of events occurred during or following a first or second ramucirumab infusion. Monitor patients during the infusion for signs of hypersensitivity reactions with resuscitation equipment readily available. Symptoms included rigors/tremors, back pain/spasms, chest pain and/or tightness, chills, flushing, dyspnoea, wheezing, hypoxia, and paraesthesia. In severe cases symptoms included bronchospasm, supraventricular tachycardia, and hypotension. Immediately and permanently discontinue ramucirumab for Grade 3 or 4 IRRs (see DOSAGE and ADMINISTRATION).

### **Hypertension**

An increased incidence of severe hypertension was observed in clinical trials. Patients with uncontrolled hypertension were excluded from the clinical trials and ramucirumab should not be commenced until their hypertension is controlled. Monitor blood pressure regularly, and withhold ramucirumab for patients who develop hypertension until it is adequately controlled. In clinical trials, hypertension was controlled in most instances with standard antihypertensives. Permanently discontinue ramucirumab if medically significant hypertension cannot be controlled with antihypertensive therapy (see PHARMACOKINETICS).

### **Impaired Wound Healing**

The impact of ramucirumab has not been evaluated in patients with serious or non-healing wounds. In a study conducted in animals, ramucirumab did not impair wound healing in monkeys. However, since ramucirumab is an antiangiogenic therapy and may have the potential to adversely affect wound healing, ramucirumab treatment should be withheld for at least 4 weeks prior to scheduled surgery. The decision to resume ramucirumab following surgical intervention should be based on clinical judgement of adequate wound healing.

If a patient develops wound healing complications during therapy, discontinue ramucirumab until the wound is fully healed (see DOSAGE and ADMINISTRATION).

### **Hepatic Impairment**

Ramucirumab should be used with caution in patients with severe liver cirrhosis (Child-Pugh B or C), cirrhosis with hepatic encephalopathy, clinically significant ascites due to cirrhosis, or hepatorenal syndrome. In these patients, ramucirumab should only be used if the potential benefits of treatment are judged to outweigh the potential risk of progressive hepatic failure (see DOSAGE and ADMINISTRATION and PHARMACOKINETICS).

## **Posterior reversible encephalopathy syndrome (PRES)/ Reversible Posterior Leukoencephalopathy Syndrome (RPLS)**

PRES (or RPLS) has been reported with a rate of <0.1% in clinical studies and in the post-market setting with ramucirumab (see Adverse Events). PRES is a neurological disorder which can present with headache, hypertension, seizure, lethargy, confusion, blindness and other visual and neurological disturbances, and can be fatal.

Confirm the diagnosis of PRES with MRI and discontinue ramucirumab in patients who develop PRES. The safety of reinitiating ramucirumab therapy in patients previously experiencing PRES is not known.

## **Fistula**

Patients may be at increased risk for the development of fistula when treated with ramucirumab. Ramucirumab treatment should be discontinued in patients who develop fistula (see DOSAGE and ADMINISTRATION).

## **Renal Impairment**

There are no safety data available for patients with severe renal impairment (eGFR < 30 ml/min) treated with ramucirumab (see DOSAGE and ADMINISTRATION).

## **Effects on Fertility**

Reproductive toxicity studies with ramucirumab have not been performed, however, animal models link angiogenesis, VEGF and VEGF Receptor 2 to critical aspects of female reproduction. Based on ramucirumab's mechanism of action, it is likely that ramucirumab will inhibit angiogenesis and result in adverse effects on fertility, including impaired ovulation, endometrial and placental function, and corpus luteum development. Treatment-related increases in follicular mineralisation of the ovary were also observed in monkeys that received ramucirumab weekly for 39 weeks at clinically relevant exposures.

There are no data on the effect of ramucirumab on human fertility. Female fertility is likely to be compromised during treatment with ramucirumab based on studies in animals.

## **Use in Pregnancy**

### **Australian Pregnancy Category D**

There are no adequate or well controlled studies of the use of ramucirumab in pregnant women or animals. IgG antibodies cross the placental barrier and ramucirumab may therefore inhibit angiogenesis in the developing fetus. As angiogenesis is critical to maintenance of pregnancy and to fetal development, this inhibition of angiogenesis may result in adverse effects on pregnancy, including fetal death and impaired heart, lung and kidney development. Ramucirumab is not recommended during pregnancy, and women of childbearing potential should be advised to use effective contraception. Women of childbearing potential or women who become pregnant during treatment should be counselled as to the potential risks of ramucirumab to the fetus and for maintaining pregnancy. Based on the half-life of ramucirumab, women of childbearing

potential should be advised to avoid becoming pregnant while receiving ramucirumab and for at least 3 months after the last dose of ramucirumab.

### **Use in Lactation**

It is unknown whether ramucirumab is excreted in human milk. Excretion in milk and oral absorption is expected to be low. As a risk to newborns/infants cannot be excluded, breast-feeding should be discontinued during treatment with ramucirumab and for at least 3 months after the last dose.

### **Paediatric Use**

The safety and effectiveness of ramucirumab has not been established in patients under 18 years of age.

In cynomolgus monkeys that received 5-50 mg/kg IV ramucirumab weekly for 39 weeks, anatomical pathology revealed adverse effects on the epiphyseal growth plate (thickening and osteochondropathy) at all doses tested. At the lowest dose the relative exposure in monkeys was less than the anticipated clinical exposure based on AUC.

### **Use in the Elderly**

In the REGARD and RAINBOW studies there has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. No reduction in starting dose is recommended.

### **Genotoxicity**

No animal studies have been performed to test ramucirumab for potential genotoxicity.

### **Carcinogenicity**

No animal studies have been performed to test ramucirumab for potential carcinogenicity.

### **Effect on laboratory tests**

Changes in laboratory test parameters (including hyponatraemia, hypokalaemia, liver function disturbances and myelosuppression) may occur with ramucirumab therapy as a single agent or in combination with chemotherapy. Electrolyte, liver function tests and a full blood count should be monitored, including during monotherapy (see also "Neutropenia" and "Hepatic Impairment").

### **Effects on ability to drive and use machines**

No studies on the effects on ability to drive or use machinery have been performed. If patients experience treatment-related symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.

## INTERACTIONS WITH OTHER MEDICINES

No drug-drug interactions were observed between ramucirumab and paclitaxel. The pharmacokinetics (PK) of paclitaxel was not affected when coadministered with ramucirumab and the PK of ramucirumab was not affected when coadministered with paclitaxel.

## ADVERSE EFFECTS

### Ramucirumab in combination with Paclitaxel for Gastric Adenocarcinoma

The following table provides the frequency and severity of adverse drug reactions (ADRs) reported in  $\geq 5\%$  of ramucirumab-treated patients in RAINBOW, a Phase 3 gastric adenocarcinoma study of ramucirumab in combination with paclitaxel.

Frequency of Adverse Drug Reactions – Very Common  $\geq 10\%$ . Refer to NCI CTCAE Criteria (Version 4.0) for each Grade of toxicity.

**Table 3: ADRs occurring at incidence rate  $\geq 5\%$  in patients receiving ramucirumab in combination with paclitaxel for gastric adenocarcinoma**

System Organ Class	Frequency	Event	Ramucirumab Plus Paclitaxel (N=327)		Placebo Plus Paclitaxel (N=329)	
			All Grades Toxicity (%)	Grade $\geq 3$ Toxicity (%)	All Grades Toxicity (%)	Grade $\geq 3$ Toxicity (%)
Blood and Lymphatic System Disorders	Very Common	Leukopenia	33.9	17.4	21.0	6.7
	Very Common	Neutropenia	54.4	40.7	31.0	18.8
	Very Common	Thrombocytopenia	13.1	1.5	6.1	1.8
Gastrointestinal Disorders	Very Common	Diarrhoea	32.4	3.7	23.1	1.5
	Very Common	Gastrointestinal haemorrhage events <sup>a</sup>	10.1	3.7	6.1	1.5
	Very Common	Stomatitis	19.6	0.6	7.3	0.6
General Disorders and Administration Site Disorders	Very Common	Fatigue/Asthenia	56.9	11.9	43.8	5.5
	Very Common	Oedema Peripheral	25.1	1.5	13.7	0.6
Metabolism and Nutrition Disorders	Very Common	Hypoalbuminaemia	11.0	1.2	4.9	0.9
Renal and Urinary Disorders	Very Common	Proteinuria	16.8	1.2	6.1	0.0
Respiratory, Thoracic, and Mediastinal Disorders	Very Common	Epistaxis	30.6	0.0	7.0	0.0
Vascular Disorder	Very Common	Hypertension <sup>b</sup>	25.1	14.7	5.8	2.7

<sup>a</sup> MedRA preferred terms included anal haemorrhage, diarrhoea haemorrhage, gastric haemorrhage, gastrointestinal haemorrhage, haematemesis, haematochezia, haemorrhoidal haemorrhage, Mallory-Weiss syndrome, melaena, oesophageal haemorrhage, rectal haemorrhage, and upper gastrointestinal haemorrhage.

<sup>b</sup> Includes hypertensive cardiomyopathy.

Clinically relevant ADRs reported in  $\geq 1\%$  and  $<5\%$  of the ramucirumab plus paclitaxel-treated patients in RAINBOW were gastrointestinal perforation (1.2% ramucirumab plus paclitaxel versus 0.3% for placebo plus paclitaxel) and sepsis (3.1% ramucirumab plus paclitaxel versus 1.8% placebo plus paclitaxel).

### Single-agent Ramucirumab for Gastric Adenocarcinoma

The following table provides the frequency and severity of adverse drug reactions (ADRs) reported in  $\geq 5\%$  of ramucirumab-treated patients in REGARD, a single-agent, placebo-controlled Phase 3 gastric adenocarcinoma study.

Frequency of Adverse Drug Reactions – Very common  $\geq 10\%$ ; Common  $\geq 1\%$  and  $<10\%$ . Refer to NCI CTCAE Criteria (Version 4.0) for each Grade of toxicity.

**Table 4: ADRs occurring at incidence rate  $\geq 5\%$  in patients receiving single-agent ramucirumab for gastric adenocarcinoma**

System Organ Class	Frequency	Event	Ramucirumab (N=236)		Placebo (N=115)	
			All Grades Toxicity (%)	Grade 3-4 Toxicity (%)	All Grades Toxicity (%)	Grade 3-4 Toxicity (%)
Gastrointestinal Disorders	Very Common	Abdominal Pain <sup>a</sup>	28.8	5.9	27.8	2.6
	Very Common	Diarrhoea	14.4	0.8	8.7	1.7
Metabolism and Nutrition Disorders	Common	Hypokalemia	5.9	2.1	5.2	0.9
	Common	Hyponatremia	5.5	3.4	1.7	0.9
Nervous System Disorders	Common	Headache	9.3	0	3.5	0
Vascular Disorders	Very Common	Hypertension	16.1	7.6	7.8	2.6

<sup>a</sup> includes hepatic pain.

Clinically relevant ADRs reported in  $\geq 1\%$  and  $<5\%$  of the ramucirumab-treated patients in REGARD were: neutropenia, arterial thromboembolic events, intestinal obstruction, epistaxis, and rash.

Clinically relevant reactions (including Grade  $\geq 3$ ) associated with antiangiogenic therapy observed in ramucirumab-treated patients across clinical trials were proteinuria, infusion-related reactions, and gastrointestinal perforations (see PRECAUTIONS and DOSAGE and ADMINISTRATION).

### Post-marketing Experience

Nervous system disorders - Rare ( $< 0.1\%$  and  $> 0.01\%$ ): Posterior reversible encephalopathy syndrome/ Reversible Posterior Leukoencephalopathy Syndrome

## DOSAGE AND ADMINISTRATION

### General

**Do not administer ramucirumab as an intravenous push or bolus.**

Only use sterile sodium chloride (0.9%) solution for injection as a diluent. Do not use dextrose as a diluent.

It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.

### Premedication

Premedication is recommended with a histamine H1 antagonist (e.g. promethazine) intravenously prior to administration of ramucirumab.

If a patient experiences a Grade 1 or 2 infusion-related reaction (IRR), premedication **must** be given for all subsequent infusions. If a patient has a second Grade 1 or 2 IRR, administer dexamethasone (or equivalent); then, for subsequent infusions, premedicate with the following or equivalent medications: promethazine hydrochloride (intravenously), paracetamol, and dexamethasone (see DOSAGE and ADMINISTRATION, Dose Adjustments).

### Gastric Adenocarcinoma

#### Ramucirumab in combination with paclitaxel

The recommended dose of ramucirumab is 8 mg/kg on Days 1 and 15 of a 28-day cycle, prior to paclitaxel infusion. The recommended dose of paclitaxel is 80 mg/m<sup>2</sup> administered by intravenous infusion over approximately 60 minutes on days 1, 8 and 15 of a 28-day cycle. Prior to each paclitaxel infusion, patients should have a complete blood count and blood chemistry performed to evaluate hepatic function. Criteria to be met prior to each paclitaxel administration are provided in Table 5.

**Table 5: Criteria to be Met Prior to Each Paclitaxel Administration**

	CRITERIA
Neutrophils	<b>Day 1:</b> $\geq 1.5 \times 10^9/L$ <b>Days 8 and 15:</b> $\geq 1.0 \times 10^9/L$
Platelets	<b>Day 1:</b> $\geq 100 \times 10^9/L$ <b>Days 8 and 15:</b> $\geq 75 \times 10^9/L$
Bilirubin	$\leq 1.5 \times$ upper limit of normal value (ULN)
AST/ALT	<b>No liver metastases:</b> ALT/AST $\leq 3 \times$ ULN <b>Liver metastases:</b> ALT/AST $\leq 5 \times$ ULN

#### Ramucirumab single agent

The recommended dose of ramucirumab as a single agent is 8 mg/kg every 2 weeks administered as an intravenous infusion over approximately 60 minutes (maximum infusion rate 25 mg/min).

## **Dose or Infusion Rate Adjustments**

### Infusion-related Reactions

Reduce the ramucirumab infusion rate by 50% for the duration of the infusion and all subsequent infusions if the patient experiences a Grade 1 or 2 IRR [per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (see DOSAGE and ADMINISTRATION, Premedication). Immediately and permanently discontinue ramucirumab for Grade 3 or 4 IRRs (see PRECAUTIONS).

### Hypertension

Monitor blood pressure during treatment with ramucirumab and treat as clinically indicated. Temporarily suspend ramucirumab for severe hypertension until controlled with medical management (see PRECAUTIONS).

### Proteinuria

Monitor for the development or worsening of proteinuria during ramucirumab therapy. If the urine protein level is  $\geq 2+$ , perform a 24-hour urine collection. Temporarily discontinue ramucirumab administration if the urine protein level is  $\geq 2$  g/24 hours. Resume treatment at a reduced dose level (to 6 mg/kg every two weeks) once the urine protein level returns to  $<2$  g/24 hours. A second dose reduction to 5 mg/kg every two weeks) is recommended if a urine protein level  $\geq 2$  g/24 hours reoccurs.

Permanently discontinue ramucirumab therapy if the urine protein level is  $>3$  g/24 hours or in the setting of nephrotic syndrome (see ADVERSE EFFECTS).

### Paclitaxel

Paclitaxel dose reductions may be applied based upon the grade of toxicity experienced by the patient. For NCI-CTCAE Grade 4 haematological toxicity or Grade 3 paclitaxel-related nonhaematological toxicity, it is recommended to reduce the paclitaxel dose by  $10 \text{ mg/m}^2$  for all following cycles. A second reduction of  $10 \text{ mg/m}^2$  is recommended if these toxicities persist or reoccur. See paclitaxel prescribing information for additional dosage and administration recommendations.

See paclitaxel prescribing information for premedication requirements.

### Impaired Wound Healing

Ramucirumab therapy should be temporarily discontinued for at least 4 weeks prior to elective surgery. Ramucirumab therapy should be temporarily discontinued if there are wound healing complications, until the wound is fully healed (see PRECAUTIONS).

### Permanently discontinue ramucirumab therapy in the event of:

Severe arterial thromboembolic events, Gastrointestinal perforations, NCI CTCAE Grade 3 or 4 bleeding (see PRECAUTIONS).

### Fistula

Ramucirumab therapy should be permanently discontinued in the event of spontaneous development of fistula (see PRECAUTIONS).

### **Use in Renal Impairment**

There have been no formal studies with ramucirumab in patients with renal impairment. No dose reductions are recommended.

### **Use in Hepatic Impairment**

There have been no formal studies with ramucirumab in patients with hepatic impairment. No dose reductions are recommended (see PRECAUTIONS).

### **Instructions for Use/Handling**

Do not administer or mix with dextrose solution.

1. Prepare the infusion solution using aseptic technique to ensure the sterility of the prepared solution.
2. Each vial is intended for use in one patient on one occasion only and discard any residue. Inspect the content of the vials prior to dilution for particulate matter and discoloration (see DESCRIPTION). If particulate matter or discolorations are identified, discard the vial.
3. Calculate the dose and volume of ramucirumab needed to prepare the infusion solution. Vials contain either 100 mg or 500 mg as a 10 mg/mL concentrate of ramucirumab. Dilute ramucirumab as required to achieve a final volume of 250 mL. Only use sterile sodium chloride (0.9%) solution for injection as a diluent.

#### In case of prefilled intravenous infusion container usage:

Based on the calculated volume of ramucirumab, remove the corresponding volume of sterile sodium chloride (0.9%) solution for injection from the prefilled 250 mL intravenous container. Aseptically transfer the calculated volume of ramucirumab to the intravenous container. The final volume in the container should be 250 mL. The container should be gently inverted to ensure adequate mixing. DO NOT FREEZE OR SHAKE the infusion solution. DO NOT dilute with other solutions or co-infuse with other electrolytes or medications.

#### In case of empty intravenous infusion container usage:

Aseptically transfer the calculated volume of ramucirumab into an empty intravenous container. Add a sufficient quantity of sterile sodium chloride (0.9%) solution for injection to the container to make the total volume 250 mL. The container should be gently inverted to ensure adequate mixing. DO NOT FREEZE OR SHAKE the infusion solution. DO NOT dilute with other solutions or co-infuse with other electrolytes or medication.

4. Parenteral drug products should be inspected visually for particulate matter prior to administration. If particulate matter is identified, discard the infusion solution.
5. Discard any unused portion of ramucirumab left in a vial, as the product contains no preservatives.

6. Administer via infusion pump. A separate line with a protein sparing 0.22 micron filter must be used for the infusion and the line must be flushed with sterile sodium chloride (0.9%) solution for injection at the end of the infusion.

## **OVERDOSAGE**

There is no data on overdose in humans. Ramucirumab has been administered in a Phase 1 study up to 10 mg/kg every two weeks without reaching a maximum tolerated dose. In case of overdose, use supportive therapy. There is no known antidote to ramucirumab overdose.

For information on the management of overdose, contact the Poison Information Centre on 131126.

## **PRESENTATION AND STORAGE CONDITIONS**

CYRAMZA is available as 10 mL and 50 mL concentrates in a vial (Type I glass) with a chlorobutyl rubber stopper, an aluminium seal and polypropylene cap.

CYRAMZA is available in packs\* of 1 of 10 mL and 1 vial of 50 mL.

\* Not all pack sizes may be marketed.

### **Storage Conditions**

CYRAMZA should be stored in a refrigerator between 2 to 8 °C. Do not freeze. Do not shake the vial.

Keep the vial in the outer carton in order to protect from light.

Chemical and physical in-use stability of CYRAMZA in sodium chloride 9 mg/mL (0.9%) solution for injection has been demonstrated for: 24 hours at 2 to 8 °C or for 4 hours at 25 °C. Do not freeze or shake the infusion solution.

## **NAME AND ADDRESS OF SPONSOR**

Eli Lilly Australia Pty. Limited  
112 Wharf Road, West Ryde, NSW 2114  
AUSTRALIA

## **POISON SCHEDULE OF THE MEDICINE**

S4

## **DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (THE ARTG)**

23Jul2015

## **DATE OF MOST RECENT AMENDMENT**

01Aug2016

CYRAMZA® is a registered trademark of Eli Lilly and Company

vA01-01\_Aug16

SUPERCEDES:cynamza-pi-v2.1-08Oct15